{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:38:16Z","timestamp":1792813096642,"version":"4.5.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,19]],"date-time":"2018-04-19T00:00:00Z","timestamp":1524096000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Saudi Pharmaceutical Journal"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.jsps.2018.04.010","type":"journal-article","created":{"date-parts":[[2018,4,20]],"date-time":"2018-04-20T10:57:37Z","timestamp":1524221857000},"page":"755-763","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"title":["A comprehensive review on Brigatinib \u2013 A wonder drug for targeted cancer therapy in non-small cell lung cancer"],"prefix":"10.1007","volume":"26","author":[{"given":"Silky","family":"Bedi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shah A.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majed M.","family":"AbuKhader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perwez","family":"Alam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasir A.","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2483-6676","authenticated-orcid":false,"given":"Asif","family":"Husain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"10.1016\/j.jsps.2018.04.010_b0005","unstructured":"ARIAD Pharmaceuticals Inc., 2017. ALUNBRIGTM (brigatinib): US prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/208772lbl.pdf (accessed 14.02.18)."},{"issue":"15","key":"10.1016\/j.jsps.2018.04.010_b0010","doi-asserted-by":"crossref","first-page":"8062","DOI":"10.1200\/jco.2015.33.15_suppl.8062","article-title":"Safety and efficacy of brigatinib (AP26113) in advanced malignancies, including ALK+ non\u2013small cell lung cancer (NSCLC)","volume":"33","author":"Camidge","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.jsps.2018.04.010_b0015","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrclinonc.2014.104","article-title":"Acquired resistance to TKIs in solid tumours: learning from lung cancer","volume":"11","author":"Camidge","year":"2014","journal-title":"Nat. Rev.Clin. Oncol."},{"issue":"1","key":"10.1016\/j.jsps.2018.04.010_b0020","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.jtho.2016.11.1643","article-title":"Brigatinib in crizotinib-refractory ALK+ NSCLC: Central assessment and updates from ALTA, a pivotal randomized phase 2 trial","volume":"12","author":"Camidge","year":"2017","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.jsps.2018.04.010_b0025","first-page":"36","article-title":"Targeted therapy for non-small cell lung cancer: current standards and the promise of the future","volume":"4","author":"Chan","year":"2015","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.jsps.2018.04.010_b0030","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrc2291","article-title":"The anaplastic lymphoma kinase in the pathogenesis of cancer","volume":"8","author":"Chiarle","year":"2008","journal-title":"Nat. Rev. Cancer"},{"issue":"15","key":"10.1016\/j.jsps.2018.04.010_b0035","doi-asserted-by":"crossref","first-page":"e443","DOI":"10.1200\/JCO.2010.34.1313","article-title":"CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib","volume":"29","author":"Costa","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.jsps.2018.04.010_b0040","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","article-title":"AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer","volume":"4","author":"Cross","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.jsps.2018.04.010_b0045","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1747-0285.2005.00316.x","article-title":"Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds","volume":"67","author":"Dalgarno","year":"2006","journal-title":"Chem. Biol. Drug Des."},{"issue":"17","key":"10.1016\/j.jsps.2018.04.010_b0050","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1158\/1078-0432.CCR-14-2789","article-title":"EGFR mutations and resistance to irreversible pyrimidine-based EGFR inhibitors","volume":"21","author":"Ercan","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.jsps.2018.04.010_b0055","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1158\/2159-8290.CD-13-0846","article-title":"The ALK inhibitor ceritinib overcomes crizotinib resistance in non\u2013small cell lung cancer","volume":"4","author":"Friboulet","year":"2014","journal-title":"Cancer Discov."},{"issue":"5","key":"10.1016\/j.jsps.2018.04.010_b0065","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/ijc.27396","article-title":"Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small cell lung cancer with mutated EGFR: a meta-analysis from six phase III randomized controlled trials","volume":"131","author":"Gao","year":"2012","journal-title":"Int. J. Cancer"},{"issue":"12","key":"10.1016\/j.jsps.2018.04.010_b0070","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S1470-2045(16)30392-8","article-title":"Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1\/2 trial","volume":"17","author":"Gettinger","year":"2016","journal-title":"Lancet Oncol."},{"issue":"14","key":"10.1016\/j.jsps.2018.04.010_b0075","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1200\/JCO.2005.08.409","article-title":"Epidermal growth factor receptor inhibitors in the treatment of non\u2013small-cell lung cancer","volume":"23","author":"Giaccone","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"23","key":"10.1016\/j.jsps.2018.04.010_b0080","doi-asserted-by":"crossref","first-page":"9296","DOI":"10.1021\/acs.jmedchem.5b01136","article-title":"Discovery of inhibitors that overcome the G1202R anaplastic lymphoma kinase resistance mutation","volume":"58","author":"Hatcher","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jsps.2018.04.010_b0085","unstructured":"http:\/\/en.pharmacodia.com\/web\/drug\/1_849.html (accessed 04.01.18)."},{"key":"10.1016\/j.jsps.2018.04.010_b0090","unstructured":"http:\/\/www.ariad.com\/research-development\/brigatinib (accessed 02.01.18)."},{"key":"10.1016\/j.jsps.2018.04.010_b0095","unstructured":"http:\/\/www.ndrugs.com\/?s=brigatinib&t=actions (accessed 12.02.18)."},{"key":"10.1016\/j.jsps.2018.04.010_b0100","unstructured":"https:\/\/www.fda.gov\/Drugs\/InformationOnDrugs\/ApprovedDrugs\/ucm555841.htm (accessed 04.01.18)."},{"issue":"4","key":"10.1016\/j.jsps.2018.04.010_b0105","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1021\/jm401805h","article-title":"Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinib","volume":"57","author":"Huang","year":"2014","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.jsps.2018.04.010_b0110","doi-asserted-by":"crossref","first-page":"4948","DOI":"10.1021\/acs.jmedchem.6b00306","article-title":"Discovery of brigatinib (AP26113), a phosphine oxide-containing, potent, orally active inhibitor of anaplastic lymphoma kinase","volume":"59","author":"Huang","year":"2016","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.jsps.2018.04.010_b0115","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1097\/PPO.0000000000000142","article-title":"Anaplastic Lymphoma Kinase (ALK) as a therapeutic target in non-small cell lung cancer","volume":"21","author":"Iams","year":"2015","journal-title":"Cancer J."},{"issue":"1","key":"10.1016\/j.jsps.2018.04.010_b0120","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1093\/annonc\/mds214","article-title":"Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin\u2013paclitaxel for chemo-na\u00efve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)","volume":"24","author":"Inoue","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jsps.2018.04.010_b0125","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.ejmech.2017.04.079","article-title":"Discovery of a potent dual ALK and EGFR T790M inhibitor","volume":"136","author":"Jang","year":"2017","journal-title":"Eur. J. Med. Chem."},{"issue":"3","key":"10.1016\/j.jsps.2018.04.010_b0130","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1039\/C7RA10533A","article-title":"LC-ESI-MS\/MS reveals the formation of reactive intermediates in brigatinib metabolism: elucidation of bioactivation pathways","volume":"8","author":"Kadi","year":"2018","journal-title":"RSC Adv."},{"key":"10.1016\/j.jsps.2018.04.010_b0135","doi-asserted-by":"crossref","unstructured":"Katayama, R., Shaw, A.T., Khan T.M., Mino-Kenudson, M., Solomon, B.J., Halmos, B., Jessop, N.A., Wain, J.C., Yeo, A.T., Benes, C., Drew, L., Saeh, J.C., Crosby, K., Sequist, L.V., Iafrate, A.J., Engelman, J.A., 2012. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci. Transl. Med. 4(120), 120ra l7.","DOI":"10.1126\/scitranslmed.3003316"},{"issue":"22","key":"10.1016\/j.jsps.2018.04.010_b0140","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1200\/JCO.2016.71.5904","article-title":"Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase\u2013positive non\u2013small-cell lung cancer: a randomized, multicenter phase II trial","volume":"35","author":"Kim","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.jsps.2018.04.010_b0145","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1056\/NEJMoa044238","article-title":"EGFR mutation and resistance of non\u2013small-cell lung cancer to gefitinib","volume":"352","author":"Kobayashi","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.jsps.2018.04.010_b0150","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1111\/cas.12275","article-title":"RET fusion gene: translation to personalized lung cancer therapy","volume":"104","author":"Kohno","year":"2013","journal-title":"Cancer Sci."},{"issue":"19","key":"10.1016\/j.jsps.2018.04.010_b0155","doi-asserted-by":"crossref","first-page":"5764","DOI":"10.1158\/1078-0432.CCR-06-0714","article-title":"Analysis of epidermal growth factor receptor gene mutation in patients with non\u2013small cell lung cancer and acquired resistance to gefitinib","volume":"12","author":"Kosaka","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"14","key":"10.1016\/j.jsps.2018.04.010_b0160","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1021\/jm801331y","article-title":"The p K BHX database: toward a better understanding of hydrogen-bond basicity for medicinal chemists","volume":"52","author":"Laurence","year":"2009","journal-title":"J. Med. Chem."},{"issue":"25","key":"10.1016\/j.jsps.2018.04.010_b0165","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for non\u2013small-cell lung cancer with mutated EGFR","volume":"362","author":"Maemondo","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jsps.2018.04.010_b0170","unstructured":"Markham, A., 2017. Brigatinib: First global approval. Drugs. 2017 June 8: 1-5 (accessed 02.02.18)."},{"issue":"14","key":"10.1016\/j.jsps.2018.04.010_b0175","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1021\/jm400402q","volume":"56","author":"Marsilje","year":"2013","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.jsps.2018.04.010_b0180","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/01.COT.0000530897.10814.2a","article-title":"Brigatnib (Alunbrig\u00ae)","volume":"40","author":"Mann","year":"2018","journal-title":"Oncol. Times"},{"key":"10.1016\/j.jsps.2018.04.010_b0185","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3389\/fonc.2014.00244","article-title":"Review of EGFR TKIs in metastatic NSCLC, including ongoing trials","volume":"4","author":"Melosky","year":"2014","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.jsps.2018.04.010_b0190","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","article-title":"Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial","volume":"11","author":"Mitsudomi","year":"2010","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.jsps.2018.04.010_b0195","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1517\/13543784.2012.690031","article-title":"Inhibitors of the anaplastic lymphoma kinase","volume":"21","author":"Mologni","year":"2012","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.jsps.2018.04.010_b0200","series-title":"Preparation method for antitumor drug AP26113","first-page":"2017016410","author":"New Patent","year":"2017"},{"issue":"8","key":"10.1016\/j.jsps.2018.04.010_b0205","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1182\/blood-2004-05-1851","article-title":"Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML","volume":"104","author":"O'Hare","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jsps.2018.04.010_b0210","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ejmech.2017.05.027","article-title":"Recent updates on third generation EGFR inhibitors and emergence of fourth generation EGFR inhibitors to combat C797S resistance","volume":"142","author":"Patel","year":"2017","journal-title":"Eur. J. Med. Chem."},{"issue":"6","key":"10.1016\/j.jsps.2018.04.010_b0215","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1158\/1535-7163.MCT-10-0792","article-title":"Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens","volume":"10","author":"Rivera","year":"2011","journal-title":"Mol. Cancer Ther."},{"issue":"3","key":"10.1016\/j.jsps.2018.04.010_b0220","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jsps.2018.04.010_b0225","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.2147\/OTT.S109295","article-title":"The activity, safety, and evolving role of brigatinib in patients with ALK-rearranged non-small cell lung cancers","volume":"10","author":"Sabari","year":"2017","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.jsps.2018.04.010_b0230","first-page":"3738","article-title":"Discovery of potent and selective orally active inhibitors of anaplastic lymphoma kinase (ALK)","volume":"69","author":"Shakespeare","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.jsps.2018.04.010_b0235","doi-asserted-by":"crossref","first-page":"355","DOI":"10.4065\/83.3.355","article-title":"Small cell lung cancer","volume":"83","author":"Sher","year":"2008","journal-title":"Mayo Clin. Proc."},{"issue":"23","key":"10.1016\/j.jsps.2018.04.010_b0240","doi-asserted-by":"crossref","first-page":"9764","DOI":"10.1021\/jm501105n","article-title":"Analysis of the elemental composition of US FDA approved drug architectures: Miniperspective","volume":"57","author":"Smith","year":"2014","journal-title":"J. Med. Chem."},{"issue":"23","key":"10.1016\/j.jsps.2018.04.010_b0245","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"First-line crizotinib versus chemotherapy in ALK-positive lung cancer","volume":"371","author":"Solomon","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"13","key":"10.1016\/j.jsps.2018.04.010_b0250","doi-asserted-by":"crossref","first-page":"4920","DOI":"10.18632\/oncotarget.2055","article-title":"Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells","volume":"5","author":"Tanimoto","year":"2014","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.jsps.2018.04.010_b0255","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/nm.3854","article-title":"Acquired EGFR C797S mutation mediates resistance to AZD9291 in non\u2013small cell lung cancer harboring EGFR T790M","volume":"21","author":"Thress","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.jsps.2018.04.010_b0260","unstructured":"Travis, W.D., Brambilla, E., M\u00fcller-Hermelink. H.K., Harris, C.C., 2010. Pathology and genetics of tumours of the lung, pleura, thymus and heart. World Health Organization Classification of Tumours. IARC Press, Lyon. ISBN92-832-2418-3."},{"issue":"8","key":"10.1016\/j.jsps.2018.04.010_b0265","doi-asserted-by":"crossref","first-page":"14768","DOI":"10.1038\/ncomms14768","article-title":"Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer","volume":"13","author":"Uchibori","year":"2017","journal-title":"Nature Commun."},{"key":"10.1016\/j.jsps.2018.04.010_b0270","unstructured":"US FDA, 2017. Brigatinib [media release] 28 April 2017. http:\/\/www. fda.gov (accessed 30.01.18)."},{"issue":"12","key":"10.1016\/j.jsps.2018.04.010_b0275","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-13-0314","article-title":"Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC","volume":"3","author":"Walter","year":"2013","journal-title":"CancerDiscov."},{"issue":"3","key":"10.1016\/j.jsps.2018.04.010_b0280","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1586\/14737140.9.3.331","article-title":"Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy","volume":"9","author":"Webb","year":"2009","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.jsps.2018.04.010_b0285","doi-asserted-by":"crossref","first-page":"e31906","DOI":"10.1371\/journal.pone.0031906","article-title":"A novel classification of lung cancer into molecular subtypes","volume":"7","author":"West","year":"2012","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.jsps.2018.04.010_b0290","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1002\/cncr.24181","article-title":"The EML4\u2013ALK fusion gene is involved in various histologic types of lung cancers from non-smokers with wild-type EGFR and KRAS","volume":"115","author":"Wong","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.jsps.2018.04.010_b0295","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jconrel.2017.05.023","article-title":"Advances in combination therapy of lung cancer: Rationales, delivery technologies and dosage regimens","volume":"260","author":"Wu","year":"2017","journal-title":"J. Control. Release"},{"issue":"2","key":"10.1016\/j.jsps.2018.04.010_b0300","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1470-2045(14)71173-8","article-title":"Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials","volume":"16","author":"Yang","year":"2015","journal-title":"Lancet Oncol."},{"issue":"15","key":"10.1016\/j.jsps.2018.04.010_b0305","doi-asserted-by":"crossref","first-page":"8117","DOI":"10.1200\/jco.2014.32.15_suppl.8117","volume":"32","author":"Yoshioka","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jsps.2018.04.010_b0310","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1158\/1078-0432.CCR-12-2246","article-title":"Analysis of mechanisms of acquired resistance to EGFR TKI therapy in 155 patients with EGFR-mutant lung cancers","volume":"19","author":"Yu","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.jsps.2018.04.010_b0315","doi-asserted-by":"crossref","first-page":"288","DOI":"10.21037\/tlcr.2016.06.07","article-title":"Non-small cell lung cancer: current treatment and future advances","volume":"5","author":"Zappa","year":"2016","journal-title":"Transl. Lung Cancer Res."},{"issue":"22","key":"10.1016\/j.jsps.2018.04.010_b0320","doi-asserted-by":"crossref","first-page":"5527","DOI":"10.1158\/1078-0432.CCR-16-0569","article-title":"The potent ALK inhibitor brigatinib (AP26113) overcomes mechanisms of resistance to first-and second-generation ALK inhibitors in preclinical models","volume":"22","author":"Zhang","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jsps.2018.04.010_b0325","doi-asserted-by":"crossref","unstructured":"Zhang, S., Wang, F., Keats, J., Ning, Y., Wardwell, S.D., Moran, L., Mohemmad, Q.K., Anjum, R., Wang, Y., Zhu, X., Miret, J.J., 2014. A potent ALK inhibitor overcomes mutations in EML4-ALK that confer resistance to PF-02341066 (PF1066). Cancer Res. 70(8), LB-298.","DOI":"10.1158\/1538-7445.AM10-LB-298"},{"issue":"8","key":"10.1016\/j.jsps.2018.04.010_b0330","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","article-title":"Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study","volume":"12","author":"Zhou","year":"2011","journal-title":"Lancet Oncol."},{"issue":"7276","key":"10.1016\/j.jsps.2018.04.010_b0335","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/nature08622","article-title":"Novel mutant-selective EGFR kinase inhibitors against EGFR T790M","volume":"462","author":"Zhou","year":"2009","journal-title":"Nature"}],"container-title":["Saudi Pharmaceutical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1319016418300902?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1319016418300902?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T17:32:01Z","timestamp":1736184721000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1319016418300902"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":66,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S1319016418300902"],"URL":"https:\/\/doi.org\/10.1016\/j.jsps.2018.04.010","relation":{},"ISSN":["1319-0164"],"issn-type":[{"value":"1319-0164","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A comprehensive review on Brigatinib \u2013 A wonder drug for targeted cancer therapy in non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Saudi Pharmaceutical Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsps.2018.04.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University.","name":"copyright","label":"Copyright"}]}}